Skip to main content
Article thumbnail
Location of Repository

Prognostic value of RKIP and p-ERK in gastric cancer

By Yoshitaka Fujimori, Mikito Inokuchi, Yoko Takagi, Keiji Kato, Kazuyuki Kojima and Kenichi Sugihara
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). AA: Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res
  2. Association: World Medical Association Declaration of Helsinki: Ethical Principales for Medical Research involving Human Subjects.[].
  3. (2010). CA: Stimulus-induced uncoupling of extracellular signal-regulated kinase phosphorylation from nuclear localization is dependent on docking domain interactions.
  4. (1999). de Velde CJ: Cancer surgery: the last 25 years. Cancer Treat Rev
  5. (1995). Decreased MAP kinase activity in human gastric adenocarcinoma.
  6. (2011). Forman D: Global cancer statistics.
  7. (2002). Global cancer statistics
  8. (1995). HM: A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer
  9. (2010). Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol
  10. (2011). Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology
  11. (2003). JG: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet
  12. (2007). Kolch W: MAP kinase signalling pathways in cancer. Oncogene
  13. (2000). Kolch W: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol
  14. (2008). Kolch W: Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability.
  15. (2005). Kolch W: Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res
  16. (1999). Kolch W: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature
  17. (2009). Lopes JM: Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch
  18. (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ ERK pathway by protein interactions.
  19. (2008). MR: Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets
  20. (2003). Prospective cohort study of comprehensive prevention to gastric cancer.
  21. (2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.
  22. (2008). Resnick MB: Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res
  23. (1995). RJ: Gastric carcinoma.
  24. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta
  25. (2005). Rosner MR: Modulation of the MAP kinase signaling cascade by Raf kinase inhibitory protein. Cell Res
  26. (2010). Solit DB: Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res
  27. (2008). Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res
  28. (2009). Sugihara K: Relation between outcomes and localisation of pmTOR expression in gastric cancer.
  29. (2008). Tan D: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NFkappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci
  30. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer
  31. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene
  32. (2004). The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol
  33. (2010). ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet
  34. (1998). Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues.
  35. (1999). Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer.
  36. (1987). Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature
  37. (2008). Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol
  38. (2006). WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.
  39. (2005). YZ: Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.